JP7603013B2 - がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー - Google Patents

がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー Download PDF

Info

Publication number
JP7603013B2
JP7603013B2 JP2021547444A JP2021547444A JP7603013B2 JP 7603013 B2 JP7603013 B2 JP 7603013B2 JP 2021547444 A JP2021547444 A JP 2021547444A JP 2021547444 A JP2021547444 A JP 2021547444A JP 7603013 B2 JP7603013 B2 JP 7603013B2
Authority
JP
Japan
Prior art keywords
cell
sequence
cells
vector
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521183A5 (enExample
JP2022521183A (ja
Inventor
ティモシー ピー． クライプ，
チュン－ユー チェン，
ブライアン ハッツェン，
マーク カリアー，
ピン－イー ワン，
ドーン チャンドラー，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2022521183A publication Critical patent/JP2022521183A/ja
Publication of JP2022521183A5 publication Critical patent/JP2022521183A5/ja
Priority to JP2024214374A priority Critical patent/JP7894428B2/ja
Application granted granted Critical
Publication of JP7603013B2 publication Critical patent/JP7603013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021547444A 2019-02-20 2020-02-19 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー Active JP7603013B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024214374A JP7894428B2 (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808264P 2019-02-20 2019-02-20
US62/808,264 2019-02-20
PCT/US2020/018806 WO2020172259A1 (en) 2019-02-20 2020-02-19 Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024214374A Division JP7894428B2 (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Publications (3)

Publication Number Publication Date
JP2022521183A JP2022521183A (ja) 2022-04-06
JP2022521183A5 JP2022521183A5 (enExample) 2023-03-02
JP7603013B2 true JP7603013B2 (ja) 2024-12-19

Family

ID=72144760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547444A Active JP7603013B2 (ja) 2019-02-20 2020-02-19 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー
JP2024214374A Active JP7894428B2 (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024214374A Active JP7894428B2 (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Country Status (11)

Country Link
US (2) US20220257760A1 (enExample)
EP (2) EP3927750A4 (enExample)
JP (2) JP7603013B2 (enExample)
KR (1) KR20210128399A (enExample)
CN (1) CN113646334B (enExample)
AU (1) AU2020226524A1 (enExample)
BR (1) BR112021015907A2 (enExample)
CA (1) CA3129506A1 (enExample)
IL (2) IL325850A (enExample)
SG (1) SG11202108924RA (enExample)
WO (1) WO2020172259A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN115124625B (zh) * 2021-03-24 2024-11-26 圣安生医股份有限公司 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用
AU2022261124A1 (en) * 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN116024267A (zh) * 2021-10-27 2023-04-28 江苏众红生物工程创药研究院有限公司 一种靶向肿瘤含有双特异性T细胞接合器编码基因的rAAV载体及其应用
JP2023176123A (ja) * 2022-05-31 2023-12-13 株式会社 光バイオ ウイルスベクター及びそれを含むがん細胞増殖抑制剤
US20260021206A1 (en) * 2022-07-25 2026-01-22 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis
AU2023314618A1 (en) * 2022-07-25 2025-03-13 Research Institute At Nationwide Children's Hospital Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006129811A (ja) 2004-11-08 2006-05-25 Hitachi Ltd 試料核酸の分析方法、分析装置および分析キット
US20110092573A1 (en) 2005-01-31 2011-04-21 Isis Pharmaceuticals, Inc. Modification of myd88 splicing using modified oligonucleotides
WO2011064319A1 (en) 2009-11-25 2011-06-03 Universität Zu Köln Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
JP2016516049A (ja) 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術
WO2018041827A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
WO2020076892A1 (en) 2018-10-09 2020-04-16 The University Of North Carolina At Chapel Hill Regulated gene editing system

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952172A (en) 1909-08-27 1910-03-15 Rudolph E Zimmer Stationery device.
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
US6506604B2 (en) 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5710037A (en) 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
KR20010040309A (ko) * 1997-12-23 2001-05-15 스티븐 에이. 서윈. 엠.디. 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법
ES2291025T3 (es) 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.
US6475786B1 (en) 1998-05-20 2002-11-05 Roche Diagnostics Gmbh Amphotropic retrovirus packaging cell line, process for its production and use thereof
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US7262049B2 (en) 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター
US6995258B1 (en) 2000-05-25 2006-02-07 City Of Hope Nucleolar targeting of therapeutics against HIV
KR100490433B1 (ko) 2003-06-10 2005-05-17 삼성전자주식회사 광주사장치의 에프쎄타 렌즈 및 광주사장치
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
US20100305002A1 (en) * 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
AU2015264263B2 (en) * 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
CN107002096A (zh) * 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
CN104592395B (zh) * 2015-01-27 2017-11-14 中国药科大学 Vegfr2单链抗体与mica融合蛋白的制备方法及用途
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
MA43134A (fr) * 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
FR3043914B1 (fr) * 2015-11-23 2017-12-29 Univ Limoges Utilisation d'oligonucleotides antisens pour produire des ig tronquees par saut d'exon pour le traitement de maladies impliquant des cellules de la lignee b.
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2017177337A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
KR102702230B1 (ko) * 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006129811A (ja) 2004-11-08 2006-05-25 Hitachi Ltd 試料核酸の分析方法、分析装置および分析キット
US20110092573A1 (en) 2005-01-31 2011-04-21 Isis Pharmaceuticals, Inc. Modification of myd88 splicing using modified oligonucleotides
WO2011064319A1 (en) 2009-11-25 2011-06-03 Universität Zu Köln Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
JP2016516049A (ja) 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
WO2018041827A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
WO2020076892A1 (en) 2018-10-09 2020-04-16 The University Of North Carolina At Chapel Hill Regulated gene editing system

Also Published As

Publication number Publication date
CA3129506A1 (en) 2020-08-27
JP7894428B2 (ja) 2026-07-23
EP4752223A2 (en) 2026-06-03
EP3927750A4 (en) 2022-11-02
CN113646334A (zh) 2021-11-12
BR112021015907A2 (pt) 2021-11-03
AU2020226524A1 (en) 2021-08-12
SG11202108924RA (en) 2021-09-29
EP4752223A3 (en) 2026-08-05
WO2020172259A1 (en) 2020-08-27
KR20210128399A (ko) 2021-10-26
EP3927750A1 (en) 2021-12-29
JP2022521183A (ja) 2022-04-06
IL325850A (en) 2026-03-01
CN113646334B (zh) 2025-09-16
JP2025026612A (ja) 2025-02-21
US20220257760A1 (en) 2022-08-18
IL285617A (en) 2021-09-30
US20260137779A1 (en) 2026-05-21

Similar Documents

Publication Publication Date Title
JP2025026612A (ja) がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー
US20250333471A1 (en) Chimeric Antigen Receptors Targeting HER2
JP7331162B2 (ja) クロロトキシン領域を含むキメラ抗原受容体
JP7297854B2 (ja) Ｐｓｃａを標的とするキメラ抗原受容体
US10676717B2 (en) Costimulatory chimeric antigen receptor T cells targeting IL13Rα2
AU2015357485A1 (en) CS1 targeted chimeric antigen receptor-modified T cells
KR20250007619A (ko) 신규 재조합 aav vp2 융합 폴리펩티드
JP7848138B2 (ja) 改変型上皮成長因子受容体及び細胞追跡におけるその使用
US20240269322A1 (en) Adeno-associated virus virions and methods of use thereof
RU2827779C2 (ru) Вирус-кодируемые регулируемые агенты, связывающие T-клетки (CATVERT) или NK-клетки (CATVERN), нацеленные на рак
WO2026080176A1 (en) Scfv-and fab-modified aav capsids and uses thereof
TW202615450A (zh) 經修飾之ａａｖ顆粒
HK40063401A (en) Chimeric antigen receptors containing a chlorotoxin domain

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241209

R150 Certificate of patent or registration of utility model

Ref document number: 7603013

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150